Polycystic ovary syndrome: Chemical pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 9, 2015, Pages 1369-1393

  Rocca, Morena Luigia ^a   Venturella, Roberta ^a   Mocciaro, Rita ^a   Di Cello, Annalisa ^a   Sacchinelli, Angela ^a   Russo, Valentina ^a   Trapasso, Simona ^a   Zullo, Fulvio ^a   Morelli, Michele ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiovascular risk; Endometrial cancer; Hyperandrogenism; Infertility; Menstrual disorder; Oligoamenorrhea; Polycystic ovary syndrome

Indexed keywords

ANTIANDROGEN; AROMATASE INHIBITOR; BROMOCRIPTINE; CHORIONIC GONADOTROPIN; CLOMIFENE; CLOMIFENE CITRATE; EFLORNITHINE; GONADORELIN ANTAGONIST; GONADOTROPIN; INSULIN SENSITIZING AGENT; KETOCONAZOLE; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; TAMOXIFEN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOMETRIUM HYPERPLASIA; EVIDENCE BASED PRACTICE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; MENSTRUATION DISORDER; OFF LABEL DRUG USE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; PHARMACEUTICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; INFERTILITY, FEMALE; LIFESTYLE; MENSTRUATION DISTURBANCES; OBSERVATIONAL STUDY; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERANDROGENISM; INFERTILITY, FEMALE; LIFE STYLE; MENSTRUATION DISTURBANCES; OBSERVATIONAL STUDIES AS TOPIC; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES;

EID: 84929912427     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1047344     Document Type: Review

References (246)

1. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293:355-9
2. Balen A. Pathogenesis of polycystic ovary syndrome-The enigma unravels? Lancet 1999;354:966-7
3. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:779-86
4. Legro RS. Polycystic ovary syndrome: current and future treatment paradigms. Am J Obstet Gynecol 1998;179(Suppl):101-8
5. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1-17
6. Balen AH. Is metformin the treatment of choice for anovulation in polycystic ovary syndrome? Nat Clin Pract Endocrinol Metab 2007;3:440-1
7. Stein FI, Leventhal LM. Amenorrhoea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-5
8. Dunaif A, Chang RJ, Franks S, Legro RS. Polycystic ovary syndrome. current controversis, from the ovary to the pancreas. Humana Press; 2008
9. Rotterdam ESRHE/ASRM 2003-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
10. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45
11. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-92
12. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;7:CD007506
13. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717-23
14. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-62
15. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
16. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88
17. Quinn M, Shinkai K, Pasch L, et al. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril 2014;101:1129-34
18. Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012;18:146-70
19. Wolf Jr JE, ShanDer D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol 2007;46:94-8
20. ACOG Committee on Practice Bulletins Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 2009;114:936-49
21. Pasquali R, Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol 2013;170:R75-90
22. Vrbkova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005;11:277-91
23. De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril 2007;88:113-17
24. Saeed R, Akram J, Changezi HU, Saeed M. Treatment of hirsutism in polycystic ovarian syndrome with Diane, 50 mcg ethinyl estradiol and 2 mg cyproterone acetate. Specialist 1993;9:109-12
25. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-10
26. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817-23
27. Batukan C, MuDerris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2006;85:436-40
28. Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:1105-20
29. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423
30. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother 2007;8:989-99
31. Romualdi D, De Cicco S, Busacca M, et al. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Invest 2013;36:636-41
32. Kriplani A, Periyasamy AJ, Agarwal N, et al. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139-46
33. Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008;24:718-23
34. Colonna L, Pacifico V, Lello S, et al. Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. J Eur Acad Dermatol Venereol 2012;26:1364-71
35. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-92
36. Guido M, Romualdi D, Campagna G, et al. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact. Reprod Sci 2010;17:767-75
37. Gomez Vazquez M, Navarra Amayuelas R, Lamarca M, et al. Ethinylestradiol/Chlormadinone acetate for use in Dermatological disorDers. Am J Clin Dermatol 2011;12:13-19
38. Uras R, Orru M, Pani F, et al. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 2010;82:131-8
39. Van Der Spuy ZM, le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003;4:CD001125
40. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 2002;77:919-27
41. Batukan C, MuDerris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007;23:38-44
42. Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 2012;98:1053-9
43. Kahraman K, Sukur YE, Atabekoglu CS, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet 2014;290:321-8
44. Rafie S, Borgelt L, Koepf ER, et al. Novel oral contraceptive for heavy menstrual bleeding: estradiol valerate and dienogest. Int J Womens Health 2013;5:313-21
45. Di Carlo C, Gargano V, Sparice S, et al. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol 2013;29:1048-50
46. Nappi RE, Serrani M, Jensen JT. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. Int J Womens Health 2014;6:711-18
47. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49
48. Mancini F, Cianciosi A, Persico N, et al. Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 2010;202:169.e1-8
49. Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest 2013;36:358-63
50. Vieira CS, Martins WP, Fernandes JB, et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception 2012;86:268-75
51. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2013;78:379-84
52. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921
53. Luque-Ramirez M, Mendieta-Azcona C, del Rey Sanchez JM, et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009;160:469-80
54. Jick SS, Hernandez RK. Risk of nonfatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing leVonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151
55. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2009;4:CD006133
56. American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2003;26:S91-3
57. Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use. MMWR Recomm Rep 2010;59:1-86
58. Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-8
59. Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-56
60. Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:392-8
61. Cibula D, Hill M, Fanta M, et al. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome? Hum Reprod 2001;16:940-4
62. Elkind-Hirsch K. Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism (BEYAZPCOS). ClinicalTrials.gov Identifier: NCT01360996 2011
63. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013;6:1-13
64. Luthy IA, Begin DJ, Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988;31:845-52
65. Terouanne B, Tahiri B, Georget V, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol 2000;160:39-49
66. Rose LI, UnDerwood RH, Newmark SR, et al. Pathophysiology of spironolactoneinduced gynecomastia. Ann Intern Med 1977;87:398-403
67. Seldin DW, Giebisch GH. Diuretic agents: clinical physiology and pharmacology. Academic Press 1997;630
68. Corvol P, Michaud A, Menard J, et al. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975;97:52-8
69. Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. J Steroid Biochem 1985;23:191-4
70. Miles RA, Cassidenti DL, Carmina E, et al. Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women. Fertil Steril 1992;58:708-12
71. Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-8
72. Flores E, Bratoeff E, Cabeza M, et al. Steroid 5alpha-reductase inhibitors. Mini Rev Med Chem 2003;3:225-37
73. Bayram F, MuDerris II, Guven M, Kelestimur F. Comparison of high dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur J Endocrinol 2002;147:467-71
74. Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986;44:261-70
75. Domecq JP, Prutsky G, Mullan RJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-Analysis. J Clin Endocrinol Metab 2013;98:4646-54
76. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94
77. Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-8
78. Grigoriou O, Papadias C, Konidaris S, et al. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Gynecol Endocrinol 1996;10:119-23
79. Fruzzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Steril 1999;71:445-51
80. Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetateestrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet 2004;87:29-33
81. Nikolaoua D, Gilling-Smith C. Hirsutism. Curr Obstet Gynaecol 2005;15:174-82
82. Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994;61:281-7
83. Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril 2005;84:1693-7
84. Falsetti L, Gambera A, Legrenzi L, et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141:361-7
85. MuDerris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73:984-7
86. Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-Acting gonadotropinreleasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8
87. Kelestimur F, Everest H, Unluhizarci K, et al. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004;150:351-4
88. Tartagni MV, Alrasheed H, Damiani GR, et al. Intermittent lowdose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. J Pediatr Adolesc Gynecol 2014;27:161-5
89. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-32
90. Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebocontrolled clinical trial. J Clin Endocrinol Metab 2009;94:469-76
91. Stabile G, Borrielli I, Artenisio AC, et al. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2014;27:177-82
92. Du Q, Wang YJ, Yang S, et al. A systematic review and meta-Analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723-30
93. Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions. Ann Pharmacother 2012;46:282-9
94. Tseng CH. A review on thiazolidinediones and bladDer cancer in human studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2014;32:1-45
95. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50
96. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46
97. Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74
98. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:241-9
99. Maciel GA, Soares Junior JM, Alves da Motta EL, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:355-60
100. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebocontrolled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:421-9
101. Gambineri A, Patton L, Vaccina A, et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebocontrolled study. J Clin Endocrinol Metab 2006;91:3970-80
102. Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized doubleblind placebo-controlled clinical trial. Fertil Steril 2010;93:2303-10
103. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149-54
104. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;90:4593-8
105. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in non obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902
106. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled crossover trial. Hum Reprod 2007;22:2967-73
107. Cosma M, Swiglo BA, Flynn DN, et al. Clinical review: insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 2008;93:1135-42
108. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509-15
109. Guido M. Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome. ClinicalTrials.gov Identifier: NCT01791647. 2012
110. Creatsas G, Hassan E, Deligeoroglou E, et al. Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog. Int J Gynecol Obstet 1993;42:147-53
111. Carr BR, Breslau NA, Givens C, et al. Oral contraceptive pills, gonadotropinreleasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J Clin Endocrinol Metab 1995;80:1169-78
112. Carmina E, Lobo RA. Gonadotropin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod 1997;12:663-6
113. Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987;27:635-42
114. Steinberger E, Rodriguez-Rigau LJ, Petak SM, et al. Glucocorticoid therapy in hyperandrogenism. Baillieres Clin Obstet Gynaecol 1990;4:457-71
115. Kaya C, Pabuccu R, Cengiz SD, DunDer I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. Exp Clin Endocrinol Diabetes 2010;118:161-6
116. Panidis D, Tziomalos K, Papadakis E, et al. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2014;80:432-8
117. Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a metaanalysis of randomized controlled trials. Exp Clin Endocrinol Diabetes 2012;120:367-75
118. Kelekci KH, Kelekci S, Yengel I, et al. Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. J Dermatolog Treat 2012;23:177-83
119. Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study. Fertil Steril 1986;46:1015-20
120. Sahin Y, Bayram F, Kelestimur F, MuDerris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest 1998;21:348-52
121. Calaf J, Lopez E, Millet A, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moDerate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab 2007;92:3446-52
122. Hagag P, SteinschneiDer M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. J Reprod Med 2014;59:455-63
123. Leelaphiwat S, Jongwutiwes T, Lertvikool S, et al. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res 2015;41(3):402-10
124. Fruzzetti F, Perini D, Lazzarini V, et al. Comparison of effects of 3 mg drospirenone plus 20 mg ethinylestradiol alone or combined with metformin or cyproterone acetate on classic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010;94:1793-8
125. Sahin I, Serter R, Karakurt F, et al. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. Gynecol Endocrinol 2004;19:115-24
126. Ibanez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12:243-52
127. Ibanez L, Lopez-Bermejo A, Daz M, et al. Low-dose pioglitazone and lowdose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf) 2009;71:351-7
128. Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a sixmonth, open-label randomized study. J Clin Endocrinol Metab 2013;98:3599-607
129. Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis 2014;24:132-9
130. Kazerooni T, Shojaei-Baghini A, Dehbashi S, et al. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010;94:2208-13
131. Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2012;9:CD001895
132. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A moDern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-32
133. Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiroinositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053
134. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5
135. Nestler JE, Jakubowicz DJ, EVans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80
136. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008;23:462-77
137. Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;CD005552
138. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053
139. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004;19:2474-83
140. Pizzo A, Lagana AS, Barbaro L. Comparison between effects of myoinositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014;30:205-8
141. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54
142. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in cotreatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010;26:275-80
143. La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2014;1-5
144. Oner G, MuDerris II. Clinical, endocrine and metabolic effects of metformin vs N-Acetyl-cysteine in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;159:127-31
145. Sacchinelli A, Venturella R, Lico D, et al. The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Resistance. Obstet Gynecol Int 2014;2014:141020
146. ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod 1995;10:1549-53
147. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorDer in 1741 patients. Hum Reprod 1995;10:2107-11
148. Bhattacharya S, Porter M, Amalraj E, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod 2009;24:3096-107
149. National Institute for Clinical Excellence Clinical Guideline. NICE clinical guideline 156. Fertility: assessment and treatment for people with fertility problems. 2013
150. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med 2014;127:912-19
151. Abu Hashim H, Ombar O, Abd Elaal I. Intrauterine insemination versus timed intercourse with clomiphene citrate in polycystic ovary syndrome: a randomized controlled trial. Acta Obstet Gynecol Scand 2011;90:344-50
152. Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012;97:1492-500
153. Kjotrod SB, Carlsen SM, Rasmussen PE, et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod 2011;26:2045-53
154. Palomba S. Metformin in Infertile PCOS Patients. ClinicalTrials.gov Identifier: NCT00501904, 2007
155. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. Cooperative Multicenter Reproductive Medicine Network. N Engl J Med 2007;356:551-66
156. Siebert TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-Analysis. Gynecol Obstet Invest 2012;73:304-13
157. Johnson MP. Metformin is reasonable option for non-obese women with infertility related to anovulatory polycystic ovary syndrome-A metaanalysis of randomised trials. Aust N Z J Obstet Gynaecol 2011;51:125-9
158. Misso ML, Costello MF, Garrubba M, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-Analysis. Hum Reprod Update 2013;19:2-11
159. Moll E, Korevaar JC, Bossuyt PMM, Van Der Veen F. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 2008;23:1830-4
160. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-Analysis. Obstet Gynecol 2008;111:959-68
161. Badawy A, State O, Abdelgawad S. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand 2007;86:218-22
162. Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-Analysis. Hum Reprod Update 2012;18:301-12
163. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014;2:CD010287
164. NIH/NICHD Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to polycystic ovary syndrome (PCOS): a randomized double-blind multicenter trial. Fertil Steril 2013;100:S51
165. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014;371:119-29
166. Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009;7:CD002249
167. Badawy A, Gibreal A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 2011;159:151-4
168. Badawy A, Allam A, Abulatta M. Extending clomiphene treatment in clomiphene-resistant women with PCOS: a randomized controlled trial. Reprod Biomed Online 2008;16:825-9
169. Badawy A, Inany H, Mosbah A, Abulatta M. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a novel protocol. Fertil Steril 2009;91:838-41
170. Kosar O, Ozaksit G, Taskin MI. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome. Arch Gynecol Obstet 2014;290:771-5
171. Elbohoty AE. Luteal phase versus follicular phase administration of clomiphene citrate in PCOS, a randomized controlled trial. ClinicalTrials.gov Identifier: NCT02024984, 2013
172. Hurst BS, Hickman JM, Matthews ML, et al. Novel clomiphene stair-step protocol reduces time to ovulation in women with polycystic ovarian syndrome. Am J Obstet Gynecol 2009;200:510
173. Deveci CD, Demir B, Sengul O, et al. Clomiphene citrate stair-step protocol vs. traditional protocol in patients with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2015;291(1):179-84
174. Palomba S, Falbo A, Giallauria F, et al. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 2010;25:2783-91
175. Palomba S, Falbo A, Orio F Jr, et al. Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age. Gynecol Endocrinol 2006;22:329-35
176. El Refaeey A, Selem A, Badawy A. Combined coenzyme Q10 and clomiphene citrate for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. Reprod Biomed Online 2014;29:119-24
177. Ismail AM, Hamed AH, Saso S, Thabet HH. Adding l-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014;180:148-52
178. Azargoon A, Ghorbani R, Faraji Z. Effects of simvastatin pretreatment on clomiphene response in clomipheneresistant women with polycystic ovary syndrome. J Family Reprod Health 2013;7:165-70
179. Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst Rev 2012;10:CD006226
180. Begum MR, Akhter S, Ehsan M, et al. Pretreatment and co-Administration of oral anti-diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene-citrate-resistant polycystic ovary syndrome. J Obstet Gynaecol Res 2013;39:966-73
181. Palomba S, Falbo A, Battista L, et al. Laparoscopic ovarian diathermy versus clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. Am J Obstet Gynecol 2010;202:577e1-8
182. Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2010;94:1405-9
183. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries: a randomized, double-blinded placebocontrolled trial. Hum Reprod 2001;16:1625-31
184. Moll E, Van Der Veen F, Van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007;13:527-37
185. Cheraghi E, Soleimani Mehranjani M, Shariatzadeh MA, et al. Co-Administration of Metformin and N-Acetyl Cysteine Fails to Improve Clinical Manifestations in PCOS Individual UnDergoing ICSI. Int J Fertil Steril 2014;8:119-28
186. Badawy A, Mosbah A, Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril 2008;89:1209-12
187. Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol 2000;10:244-7
188. Mitwally MFM, Casper RF. Use of an AI for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2000;75:305-9
189. Elnashar A, Fouad H, Eldosoky M, Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006;85:511-13
190. Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomipheneresistant women with polycystic ovary syndrome: a novel protocol. Fertil Steril 2009;92:236-9
191. Kamath MS, Aleyamma TK, Chandy A, George K. Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2010;94:2857-9
192. Abu Hashim H, Mashaly AM, Badawy A. Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Arch Gynecol Obstet 2010;282:567-71
193. Abd Elgafor I. Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomipheneresistant infertile women with polycystic ovarian syndrome. Arch Gynecol Obstet 2013;288:119-23
194. Costello MF, Misso ML, Wong J, et al. The treatment of infertility in polycystic ovary syndrome: a brief update. Aust N Z J Obstet Gynaecol 2012;52:400-3
195. Nugent D, Vandekerckhove P, Hughes E, et al. Gonadotropin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000;4:CD000410
196. Bayram N, Van Wely M, Van Der Veen F. Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001;2:CD002121
197. Balen A, Platteau P, AnDersen AN, et al. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod 2007;22:1816-23
198. Homburg R, Howles CM. Low dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, reflections and refinements. Hum Reprod Update 1999;5:493-9
199. Casadei L, Puca F, Emidi E, et al. Sequential low-dose step-up and stepdown protocols with recombinant follicle-stimulating hormone in polycystic ovary syndrome: prospective comparison with step-down protocol. Arch Gynecol Obstet 2012;286:1291-7
200. Homburg R, Hendriks ML, Konig TE, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 2012;27:468-73
201. Lin H, Li Y, Li L, et al. Is a GnRH antagonist protocol better in PCOS patients? A meta-Analysis of RCTs. PLoS One 2014;9:e91796
202. Westergaard LW, Bossuyt PM, Van Der Veen F, Van Wely M. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2011;2:CD003973
203. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;11:CD001750
204. Xiao J, Chen S, Zhang C, Chang S. Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome unDergoing IVF: a systematic review and meta analysis. Gynecol Endocrinol 2013;29:187-91
205. Youssef MA, Van Der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-Assisted reproductive technology. Cochrane Database Syst Rev 2014;10:CD008046
206. ONeill KE, Senapati S, Dokras A. Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome. Fertil Steril 2014;pii:S0015-282(14)02224-9
207. Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin-releasing hormone antagonist protocol-The protocol of choice for the polycystic ovary syndrome patient unDergoing controlled ovarian stimulation. Acta Obstet Gynecol Scand 2012;91:643-7
208. Ghanem ME, Elboghdady LA, Hassan M, et al. Clomiphene citrate cotreatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet 2013;30:1477-85
209. Figueiredo JB, Nastri CO, Vieira AD, Martins WP. Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women unDergoing assisted reproductive techniques: systematic review and meta-Analysis. Arch Gynecol Obstet 2013;287:779-90
210. Costello MF, Chapman M, Conway U. A systematic review and meta-Analysis of randomized controlled trials on metformin co-Administration during gonadotropin ovulation induction or IVF in women with polycystic ovary syndrome. Hum Reprod 2006;21:1387-99
211. Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-Analysis of randomized controlled trials. Reprod Biol Endocrinol 2014;12:3
212. Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009;2:CD006105
213. Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotropins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and metaanalysis of randomised controlled trials. BJOG 2013;120:267-76
214. Palomba S, Falbo A, Carrillo L, et al. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril 2011;96:1384-90.e4
215. Palomba S, Falbo A, Di Cello A, et al. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertil Steril 2011;96:1128-33
216. Kumbak B, Kahraman S. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients unDergoing in vitro fertilization. Acta Obstet Gynecol Scand 2009;88:563-8
217. Decanter C, Robin G, Thomas P, et al. First intention IVF protocol for polycystic ovaries: does oral contraceptive pill pretreatment influence COH outcome? Reprod Biol Endocrinol 2013;11:54
218. Haydardedeoglu B, Kilicdag EB, Parlakgumus AH, Zeyneloglu HB. IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Arch Gynecol Obstet 2012;286:763-9
219. Papanikolaou EG, Polyzos NP, Humaidan P, et al. Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 2011;9:85
220. Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on womens health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28-38.e25
221. AnDerson SA, Barry JA, Hardiman PJ. Risk of coronary heart disease and risk of stroke in women with polycystic ovary syndrome: a systematic review and meta-Analysis. Int J Cardiol 2014;176:486-7
222. Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2014;30:367-71
223. Ilie IR, Marian I, Mocan T, et al. Ethinylestradiol30g-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord 2012;12:9
224. Kaya MG, Calapkorur B, Karaca Z, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012;77:885-92
225. Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006;21:80-9
226. Studen KB, Sebestjen M, Pfeifer M, Prezelj J. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:389-95
227. Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 2011;10:CD008565
228. Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol Oncol 2014;132:248-53
229. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27:1327-31
230. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-31
231. Reed SD, Newton KM, Garcia RL, et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010;116:365-73
232. Gallos ID, Krishan P, Shehmar M, et al. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Hum Reprod 2013;28:1231-6
233. Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007;50:907-17
234. Lin M, Xu X, Wang Y, et al. Evaluation of a leVonorgestrel-releasing intrauterine system for treating endometrial hyperplasia in patients with polycystic ovary syndrome. Gynecol Obstet Invest 2014;78:41-4
235. Stanosz S, Von Mach-Szczypinski J, Sieja K, Kociuszkiewicz J. Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1A/G1) in young women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2014;26:jc20141693
236. Shao R, Li X, Feng Y, et al. Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res 2014;33:41
237. Erdemoglu E, Guney M, Giray SG, et al. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2009;145:195-9
238. Wang YL, Xie Y, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-20
239. Session DR, Kalli KR, Tummon IS, et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003;17:405-7
240. Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;196:402
241. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465-7
242. Venturella R, Lico D, Sarica A, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters. J Ovarian Res 2015;8:21
243. Viollet B, Guigas B, Sanz Garcia N, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012;122:253
244. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-24
245. Kurzthaler D, Hadziomerovic-Pekic D, Wildt L, Seeber BE. Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulinsensitizing effects. Reprod Biol Endocrinol 2014;12:98
246. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyper-Androgenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54